| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoglycemic Agents | 15 | 2021 | 212 | 3.690 |
Why?
|
| Cough | 13 | 2021 | 182 | 3.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 19 | 2018 | 674 | 3.390 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 15 | 2014 | 566 | 3.180 |
Why?
|
| Thiazolidinediones | 10 | 2015 | 52 | 2.960 |
Why?
|
| Cardiovascular Diseases | 15 | 2017 | 827 | 2.540 |
Why?
|
| Scopolamine Derivatives | 9 | 2014 | 12 | 2.510 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 6 | 2024 | 151 | 2.350 |
Why?
|
| Cholinergic Antagonists | 7 | 2024 | 30 | 2.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 8 | 2019 | 212 | 2.090 |
Why?
|
| Warfare | 12 | 2014 | 33 | 2.090 |
Why?
|
| Humans | 184 | 2025 | 59520 | 2.040 |
Why?
|
| Gastrointestinal Hemorrhage | 5 | 2020 | 86 | 2.010 |
Why?
|
| Randomized Controlled Trials as Topic | 25 | 2024 | 673 | 1.910 |
Why?
|
| Pancreatitis | 7 | 2015 | 101 | 1.880 |
Why?
|
| Drugs, Generic | 3 | 2018 | 17 | 1.750 |
Why?
|
| Alzheimer Disease | 4 | 2024 | 551 | 1.700 |
Why?
|
| Algorithms | 6 | 2022 | 990 | 1.450 |
Why?
|
| Decision Support Techniques | 5 | 2020 | 180 | 1.440 |
Why?
|
| Dabigatran | 5 | 2023 | 23 | 1.440 |
Why?
|
| Delivery of Health Care | 7 | 2021 | 421 | 1.410 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 4 | 2017 | 51 | 1.400 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2018 | 154 | 1.290 |
Why?
|
| Anticoagulants | 10 | 2023 | 487 | 1.270 |
Why?
|
| Pneumonia | 6 | 2018 | 270 | 1.260 |
Why?
|
| Research Design | 11 | 2023 | 566 | 1.180 |
Why?
|
| Benzazepines | 3 | 2012 | 21 | 1.170 |
Why?
|
| Quinoxalines | 3 | 2012 | 35 | 1.140 |
Why?
|
| Inappropriate Prescribing | 2 | 2024 | 67 | 1.120 |
Why?
|
| Aortic Aneurysm | 2 | 2018 | 84 | 1.110 |
Why?
|
| Myocardial Ischemia | 3 | 2014 | 109 | 1.110 |
Why?
|
| Myocardial Infarction | 9 | 2018 | 864 | 1.100 |
Why?
|
| United States Food and Drug Administration | 5 | 2018 | 95 | 1.100 |
Why?
|
| Bronchodilator Agents | 4 | 2014 | 97 | 1.100 |
Why?
|
| Clinical Trials as Topic | 9 | 2018 | 442 | 1.060 |
Why?
|
| Administration, Inhalation | 12 | 2014 | 110 | 1.060 |
Why?
|
| Evidence-Based Medicine | 8 | 2019 | 452 | 1.040 |
Why?
|
| Aged | 38 | 2025 | 13342 | 1.000 |
Why?
|
| Male | 55 | 2025 | 27574 | 0.990 |
Why?
|
| Warfarin | 6 | 2015 | 109 | 0.980 |
Why?
|
| Atrial Fibrillation | 6 | 2023 | 798 | 0.960 |
Why?
|
| Risk Assessment | 19 | 2020 | 1915 | 0.950 |
Why?
|
| Dementia | 2 | 2024 | 247 | 0.950 |
Why?
|
| Female | 61 | 2025 | 30920 | 0.950 |
Why?
|
| Renal Insufficiency | 2 | 2023 | 62 | 0.940 |
Why?
|
| Glucagon-Like Peptide 1 | 3 | 2018 | 21 | 0.910 |
Why?
|
| Ipratropium | 3 | 2014 | 7 | 0.880 |
Why?
|
| Human Rights | 5 | 2008 | 16 | 0.870 |
Why?
|
| Nicotinic Agonists | 3 | 2012 | 39 | 0.860 |
Why?
|
| Asthma | 2 | 2022 | 420 | 0.860 |
Why?
|
| Anti-Bacterial Agents | 4 | 2018 | 724 | 0.850 |
Why?
|
| Primary Prevention | 3 | 2019 | 137 | 0.820 |
Why?
|
| Electronic Health Records | 3 | 2022 | 352 | 0.820 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2022 | 30 | 0.810 |
Why?
|
| Periodicals as Topic | 2 | 2020 | 173 | 0.800 |
Why?
|
| Prescription Drugs | 3 | 2018 | 50 | 0.790 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 114 | 0.780 |
Why?
|
| Adult | 36 | 2025 | 15789 | 0.770 |
Why?
|
| Early Detection of Cancer | 2 | 2025 | 265 | 0.770 |
Why?
|
| Review Literature as Topic | 5 | 2016 | 33 | 0.760 |
Why?
|
| Heart Failure | 7 | 2016 | 867 | 0.740 |
Why?
|
| Biological Products | 1 | 2022 | 94 | 0.740 |
Why?
|
| Antiparkinson Agents | 1 | 2021 | 9 | 0.730 |
Why?
|
| Dopamine Antagonists | 1 | 2021 | 15 | 0.730 |
Why?
|
| Fluoroquinolones | 2 | 2018 | 30 | 0.720 |
Why?
|
| HIV Infections | 9 | 2017 | 921 | 0.700 |
Why?
|
| Middle Aged | 38 | 2025 | 16277 | 0.700 |
Why?
|
| Public Health | 3 | 2007 | 180 | 0.690 |
Why?
|
| Nepal | 13 | 2016 | 93 | 0.690 |
Why?
|
| Lung Neoplasms | 3 | 2025 | 552 | 0.680 |
Why?
|
| Tiotropium Bromide | 8 | 2014 | 14 | 0.680 |
Why?
|
| Vaccination Coverage | 1 | 2019 | 6 | 0.670 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 122 | 0.670 |
Why?
|
| Practice Guidelines as Topic | 6 | 2018 | 703 | 0.670 |
Why?
|
| Hospitalization | 5 | 2022 | 1283 | 0.670 |
Why?
|
| Intracranial Hemorrhages | 1 | 2020 | 60 | 0.660 |
Why?
|
| Wernicke Encephalopathy | 4 | 2007 | 4 | 0.660 |
Why?
|
| Risk Factors | 20 | 2018 | 5017 | 0.650 |
Why?
|
| Testosterone | 2 | 2016 | 111 | 0.650 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 188 | 0.650 |
Why?
|
| Decision Making | 4 | 2025 | 390 | 0.640 |
Why?
|
| Treatment Outcome | 17 | 2023 | 5183 | 0.640 |
Why?
|
| Human Rights Abuses | 3 | 2007 | 3 | 0.630 |
Why?
|
| Glucocorticoids | 2 | 2011 | 171 | 0.620 |
Why?
|
| beta-Alanine | 2 | 2015 | 9 | 0.620 |
Why?
|
| Cardiovascular System | 1 | 2019 | 42 | 0.620 |
Why?
|
| Immunologic Factors | 1 | 2019 | 99 | 0.620 |
Why?
|
| Myocarditis | 1 | 2019 | 61 | 0.610 |
Why?
|
| Refugees | 4 | 2008 | 65 | 0.610 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2019 | 354 | 0.610 |
Why?
|
| Databases, Factual | 5 | 2021 | 838 | 0.600 |
Why?
|
| Cause of Death | 3 | 2019 | 200 | 0.600 |
Why?
|
| Thiophenes | 2 | 2015 | 43 | 0.600 |
Why?
|
| Patient Participation | 1 | 2020 | 211 | 0.600 |
Why?
|
| Morpholines | 2 | 2015 | 86 | 0.600 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2015 | 60 | 0.600 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 220 | 0.600 |
Why?
|
| Statistics as Topic | 1 | 2018 | 147 | 0.590 |
Why?
|
| Stroke | 6 | 2023 | 1139 | 0.590 |
Why?
|
| Benzimidazoles | 2 | 2015 | 59 | 0.590 |
Why?
|
| United States | 18 | 2023 | 7514 | 0.590 |
Why?
|
| Amphetamine | 1 | 2017 | 11 | 0.580 |
Why?
|
| Herpes Zoster | 1 | 2017 | 24 | 0.570 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 5089 | 0.560 |
Why?
|
| Thyroxine | 1 | 2017 | 53 | 0.560 |
Why?
|
| Guidelines as Topic | 4 | 2012 | 158 | 0.560 |
Why?
|
| Atherosclerosis | 1 | 2018 | 147 | 0.560 |
Why?
|
| Incretins | 1 | 2016 | 6 | 0.560 |
Why?
|
| Incidence | 9 | 2022 | 1238 | 0.550 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 72 | 0.550 |
Why?
|
| Antithrombins | 1 | 2017 | 16 | 0.550 |
Why?
|
| Disasters | 2 | 2014 | 28 | 0.530 |
Why?
|
| Communication | 5 | 2025 | 554 | 0.520 |
Why?
|
| Bronchitis | 2 | 2020 | 25 | 0.510 |
Why?
|
| Health Services Accessibility | 6 | 2009 | 542 | 0.510 |
Why?
|
| Pharyngitis | 2 | 2006 | 12 | 0.510 |
Why?
|
| Streptococcus pyogenes | 2 | 2006 | 27 | 0.500 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2016 | 142 | 0.500 |
Why?
|
| Rhabdomyolysis | 2 | 2006 | 26 | 0.490 |
Why?
|
| Fluorobenzenes | 2 | 2005 | 5 | 0.490 |
Why?
|
| Streptococcal Infections | 2 | 2006 | 77 | 0.490 |
Why?
|
| Patient Education as Topic | 3 | 2024 | 446 | 0.490 |
Why?
|
| Pharmacoepidemiology | 1 | 2014 | 11 | 0.480 |
Why?
|
| Fractures, Bone | 3 | 2011 | 139 | 0.480 |
Why?
|
| Vena Cava Filters | 2 | 2014 | 20 | 0.480 |
Why?
|
| Risk | 7 | 2020 | 372 | 0.480 |
Why?
|
| Heptanoic Acids | 2 | 2004 | 21 | 0.470 |
Why?
|
| Pyrroles | 2 | 2004 | 50 | 0.470 |
Why?
|
| Pyrimidines | 2 | 2005 | 122 | 0.460 |
Why?
|
| Sulfonamides | 2 | 2005 | 123 | 0.460 |
Why?
|
| Embolism, Paradoxical | 1 | 2014 | 14 | 0.450 |
Why?
|
| Medication Adherence | 2 | 2015 | 255 | 0.450 |
Why?
|
| Developing Countries | 4 | 2008 | 84 | 0.440 |
Why?
|
| Bariatric Surgery | 3 | 2013 | 45 | 0.440 |
Why?
|
| Urinary Retention | 2 | 2011 | 30 | 0.440 |
Why?
|
| Azasteroids | 1 | 2013 | 2 | 0.440 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2013 | 7 | 0.440 |
Why?
|
| Health Planning Guidelines | 1 | 2013 | 31 | 0.430 |
Why?
|
| Valproic Acid | 1 | 2013 | 25 | 0.430 |
Why?
|
| Age Factors | 8 | 2021 | 1518 | 0.430 |
Why?
|
| Relief Work | 3 | 2007 | 13 | 0.430 |
Why?
|
| Consensus | 3 | 2018 | 194 | 0.430 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 809 | 0.420 |
Why?
|
| Antipsychotic Agents | 3 | 2024 | 312 | 0.420 |
Why?
|
| Biomedical Research | 3 | 2013 | 250 | 0.420 |
Why?
|
| Physician-Patient Relations | 3 | 2025 | 388 | 0.420 |
Why?
|
| Meta-Analysis as Topic | 5 | 2015 | 77 | 0.420 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2013 | 52 | 0.420 |
Why?
|
| Anticonvulsants | 1 | 2013 | 95 | 0.420 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 1464 | 0.420 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 319 | 0.410 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 317 | 0.410 |
Why?
|
| Insulin | 1 | 2016 | 687 | 0.410 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2012 | 8 | 0.400 |
Why?
|
| Tobacco Use Cessation | 1 | 2012 | 30 | 0.400 |
Why?
|
| Epilepsy | 1 | 2013 | 108 | 0.400 |
Why?
|
| Polypharmacy | 2 | 2024 | 62 | 0.400 |
Why?
|
| Macular Edema | 1 | 2012 | 24 | 0.400 |
Why?
|
| Chronic Disease | 6 | 2021 | 735 | 0.390 |
Why?
|
| Bupropion | 1 | 2011 | 8 | 0.390 |
Why?
|
| Cohort Studies | 5 | 2021 | 2442 | 0.390 |
Why?
|
| Acute Disease | 6 | 2020 | 659 | 0.390 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2013 | 164 | 0.380 |
Why?
|
| Diabetic Angiopathies | 2 | 2008 | 25 | 0.380 |
Why?
|
| Mucociliary Clearance | 1 | 2021 | 6 | 0.380 |
Why?
|
| Wounds and Injuries | 1 | 2014 | 237 | 0.370 |
Why?
|
| Reflex | 1 | 2021 | 28 | 0.370 |
Why?
|
| Venoms | 3 | 2016 | 11 | 0.370 |
Why?
|
| Administration, Oral | 5 | 2023 | 344 | 0.370 |
Why?
|
| Opportunistic Infections | 1 | 2011 | 27 | 0.370 |
Why?
|
| Autistic Disorder | 1 | 2013 | 167 | 0.360 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 4 | 2021 | 11 | 0.360 |
Why?
|
| Nicotine | 1 | 2011 | 109 | 0.360 |
Why?
|
| Product Surveillance, Postmarketing | 4 | 2012 | 24 | 0.350 |
Why?
|
| Respiratory Tract Infections | 1 | 2011 | 80 | 0.350 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 1551 | 0.350 |
Why?
|
| Bronchitis, Chronic | 1 | 2020 | 13 | 0.340 |
Why?
|
| Lower Extremity | 3 | 2021 | 145 | 0.340 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2011 | 202 | 0.340 |
Why?
|
| Eosinophilia | 1 | 2020 | 28 | 0.340 |
Why?
|
| Suicide | 1 | 2011 | 123 | 0.340 |
Why?
|
| Quality of Life | 3 | 2020 | 1117 | 0.330 |
Why?
|
| Retrospective Studies | 10 | 2023 | 6011 | 0.330 |
Why?
|
| Child | 11 | 2020 | 4306 | 0.330 |
Why?
|
| Outpatients | 2 | 2020 | 131 | 0.330 |
Why?
|
| Primary Health Care | 3 | 2024 | 647 | 0.330 |
Why?
|
| International Cooperation | 5 | 2008 | 82 | 0.330 |
Why?
|
| Mortality | 3 | 2018 | 159 | 0.320 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 2 | 2021 | 20 | 0.320 |
Why?
|
| Kidney Failure, Chronic | 2 | 2008 | 193 | 0.320 |
Why?
|
| Postoperative Complications | 4 | 2013 | 1135 | 0.320 |
Why?
|
| Diphosphonates | 1 | 2009 | 35 | 0.320 |
Why?
|
| Observational Studies as Topic | 3 | 2019 | 60 | 0.320 |
Why?
|
| Outsourced Services | 1 | 2008 | 3 | 0.320 |
Why?
|
| Health | 2 | 2006 | 32 | 0.320 |
Why?
|
| Depression | 3 | 2014 | 857 | 0.310 |
Why?
|
| Polyethylene Glycols | 2 | 2023 | 162 | 0.310 |
Why?
|
| Whooping Cough | 1 | 2018 | 15 | 0.310 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 77 | 0.310 |
Why?
|
| Pregnancy Complications | 1 | 2013 | 391 | 0.310 |
Why?
|
| Bone Density Conservation Agents | 1 | 2009 | 48 | 0.310 |
Why?
|
| Publication Bias | 4 | 2012 | 21 | 0.310 |
Why?
|
| Emigration and Immigration | 2 | 2008 | 25 | 0.310 |
Why?
|
| Bronchiolitis, Viral | 1 | 2018 | 4 | 0.310 |
Why?
|
| Mass Screening | 3 | 2025 | 647 | 0.310 |
Why?
|
| Disaster Planning | 3 | 2015 | 51 | 0.300 |
Why?
|
| Stomatitis | 1 | 2008 | 7 | 0.300 |
Why?
|
| Attitude to Health | 2 | 2008 | 275 | 0.300 |
Why?
|
| Simvastatin | 2 | 2005 | 28 | 0.300 |
Why?
|
| Antiviral Agents | 2 | 2023 | 314 | 0.300 |
Why?
|
| Adolescent | 9 | 2020 | 5932 | 0.290 |
Why?
|
| Secondary Prevention | 2 | 2019 | 153 | 0.290 |
Why?
|
| Hemorrhage | 3 | 2023 | 277 | 0.290 |
Why?
|
| Interferon-alpha | 1 | 2008 | 98 | 0.290 |
Why?
|
| Civil Disorders | 1 | 2007 | 2 | 0.290 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2018 | 95 | 0.280 |
Why?
|
| Peptides | 3 | 2016 | 549 | 0.280 |
Why?
|
| Patient Advocacy | 1 | 2007 | 32 | 0.280 |
Why?
|
| Lisinopril | 1 | 2006 | 4 | 0.280 |
Why?
|
| Child Welfare | 2 | 2009 | 54 | 0.270 |
Why?
|
| Young Adult | 7 | 2021 | 4332 | 0.270 |
Why?
|
| Critical Illness | 1 | 2020 | 332 | 0.270 |
Why?
|
| Renal Dialysis | 1 | 2008 | 185 | 0.270 |
Why?
|
| Contrast Media | 2 | 2008 | 410 | 0.270 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2017 | 107 | 0.270 |
Why?
|
| Sample Size | 4 | 2023 | 59 | 0.270 |
Why?
|
| Smoking Cessation | 1 | 2011 | 531 | 0.260 |
Why?
|
| Information Dissemination | 1 | 2007 | 117 | 0.260 |
Why?
|
| Pulmonary Alveoli | 1 | 2006 | 43 | 0.260 |
Why?
|
| Amiodarone | 1 | 2006 | 21 | 0.260 |
Why?
|
| Hydralazine | 1 | 2006 | 1 | 0.260 |
Why?
|
| Clinical Clerkship | 1 | 2006 | 83 | 0.260 |
Why?
|
| Influenza, Human | 1 | 2018 | 193 | 0.260 |
Why?
|
| Self Care | 1 | 2008 | 211 | 0.260 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2006 | 142 | 0.260 |
Why?
|
| Physicians | 4 | 2025 | 436 | 0.250 |
Why?
|
| Qualitative Research | 4 | 2025 | 612 | 0.250 |
Why?
|
| Vasodilator Agents | 1 | 2006 | 61 | 0.250 |
Why?
|
| Internal Medicine | 1 | 2006 | 148 | 0.250 |
Why?
|
| Religion and Medicine | 1 | 2005 | 22 | 0.250 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2006 | 93 | 0.250 |
Why?
|
| Myelography | 1 | 2005 | 4 | 0.250 |
Why?
|
| Vasoconstrictor Agents | 1 | 2006 | 64 | 0.250 |
Why?
|
| Iopamidol | 1 | 2005 | 16 | 0.250 |
Why?
|
| Cocaine-Related Disorders | 1 | 2006 | 75 | 0.250 |
Why?
|
| Patient Selection | 5 | 2015 | 446 | 0.250 |
Why?
|
| Aging | 1 | 2021 | 723 | 0.250 |
Why?
|
| Prospective Studies | 3 | 2024 | 3101 | 0.240 |
Why?
|
| Religion | 1 | 2005 | 33 | 0.240 |
Why?
|
| Bariatrics | 1 | 2005 | 1 | 0.240 |
Why?
|
| Cocaine | 1 | 2006 | 86 | 0.240 |
Why?
|
| Pharynx | 1 | 2005 | 21 | 0.240 |
Why?
|
| Aminopyridines | 2 | 2016 | 23 | 0.240 |
Why?
|
| Carotid Stenosis | 1 | 2006 | 105 | 0.240 |
Why?
|
| Community Health Services | 1 | 2006 | 128 | 0.240 |
Why?
|
| Disease Outbreaks | 1 | 2005 | 105 | 0.240 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2005 | 27 | 0.240 |
Why?
|
| Formularies as Topic | 1 | 2004 | 2 | 0.240 |
Why?
|
| Benzamides | 2 | 2016 | 51 | 0.240 |
Why?
|
| Patient-Centered Care | 2 | 2019 | 249 | 0.240 |
Why?
|
| Deprescriptions | 1 | 2024 | 22 | 0.240 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 71 | 0.230 |
Why?
|
| Lung Diseases | 1 | 2006 | 164 | 0.230 |
Why?
|
| Referral and Consultation | 1 | 2008 | 409 | 0.230 |
Why?
|
| Social Justice | 1 | 2004 | 30 | 0.230 |
Why?
|
| Societies, Medical | 1 | 2006 | 330 | 0.230 |
Why?
|
| Seizures | 1 | 2005 | 118 | 0.230 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2006 | 159 | 0.230 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 2329 | 0.230 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 266 | 0.230 |
Why?
|
| Healthcare Disparities | 1 | 2008 | 330 | 0.230 |
Why?
|
| Potentially Inappropriate Medication List | 1 | 2024 | 14 | 0.230 |
Why?
|
| Acute Kidney Injury | 1 | 2006 | 131 | 0.230 |
Why?
|
| Bias | 3 | 2014 | 106 | 0.220 |
Why?
|
| Health Services | 1 | 2004 | 85 | 0.220 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 282 | 0.220 |
Why?
|
| Vaccination | 5 | 2024 | 337 | 0.220 |
Why?
|
| Obesity | 2 | 2013 | 1186 | 0.220 |
Why?
|
| Drug Therapy, Combination | 5 | 2018 | 436 | 0.220 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2009 | 741 | 0.220 |
Why?
|
| Tenofovir | 1 | 2023 | 8 | 0.220 |
Why?
|
| Socioeconomic Factors | 5 | 2016 | 781 | 0.210 |
Why?
|
| Adenine | 1 | 2023 | 46 | 0.210 |
Why?
|
| Child Abuse | 1 | 2004 | 87 | 0.210 |
Why?
|
| Blood Glucose | 3 | 2018 | 471 | 0.210 |
Why?
|
| Rivaroxaban | 3 | 2023 | 21 | 0.210 |
Why?
|
| Military Personnel | 1 | 2004 | 97 | 0.210 |
Why?
|
| Heart Transplantation | 1 | 2004 | 159 | 0.210 |
Why?
|
| Focus Groups | 1 | 2024 | 292 | 0.210 |
Why?
|
| Health Expenditures | 1 | 2004 | 115 | 0.200 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2009 | 137 | 0.200 |
Why?
|
| Ivermectin | 1 | 2022 | 10 | 0.200 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 88 | 0.200 |
Why?
|
| Intracranial Aneurysm | 1 | 2006 | 335 | 0.200 |
Why?
|
| Kidney | 2 | 2023 | 395 | 0.200 |
Why?
|
| Varenicline | 2 | 2011 | 11 | 0.190 |
Why?
|
| Venous Thromboembolism | 2 | 2013 | 140 | 0.190 |
Why?
|
| Hypertension | 1 | 2007 | 601 | 0.190 |
Why?
|
| Caregivers | 1 | 2024 | 216 | 0.190 |
Why?
|
| International Classification of Diseases | 2 | 2019 | 143 | 0.190 |
Why?
|
| Medication Systems | 1 | 2021 | 18 | 0.190 |
Why?
|
| Pilot Projects | 3 | 2017 | 919 | 0.180 |
Why?
|
| Double-Blind Method | 3 | 2023 | 680 | 0.180 |
Why?
|
| Delphi Technique | 3 | 2019 | 82 | 0.180 |
Why?
|
| Diuretics | 1 | 2021 | 58 | 0.180 |
Why?
|
| Calcium Channel Blockers | 1 | 2021 | 56 | 0.180 |
Why?
|
| Pharmacy | 1 | 2021 | 18 | 0.180 |
Why?
|
| Data Collection | 2 | 2019 | 384 | 0.180 |
Why?
|
| Ambulatory Care | 3 | 2023 | 300 | 0.180 |
Why?
|
| Proton Pump Inhibitors | 2 | 2019 | 39 | 0.180 |
Why?
|
| Case-Control Studies | 3 | 2013 | 1063 | 0.180 |
Why?
|
| Safety Management | 2 | 2012 | 143 | 0.170 |
Why?
|
| Medication Errors | 1 | 2021 | 116 | 0.170 |
Why?
|
| Anti-Infective Agents | 1 | 2022 | 139 | 0.170 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1449 | 0.170 |
Why?
|
| Vaccines | 1 | 2021 | 97 | 0.170 |
Why?
|
| Drug Labeling | 2 | 2012 | 27 | 0.170 |
Why?
|
| Peripheral Arterial Disease | 2 | 2020 | 155 | 0.170 |
Why?
|
| Prevalence | 5 | 2013 | 1281 | 0.170 |
Why?
|
| Pharmacists | 1 | 2021 | 123 | 0.170 |
Why?
|
| Death Certificates | 1 | 2019 | 9 | 0.170 |
Why?
|
| Vulnerable Populations | 2 | 2013 | 83 | 0.160 |
Why?
|
| Prognosis | 3 | 2014 | 1572 | 0.160 |
Why?
|
| Patient Safety | 2 | 2012 | 243 | 0.160 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 33 | 0.160 |
Why?
|
| Medicare | 1 | 2023 | 601 | 0.160 |
Why?
|
| Reminder Systems | 1 | 2019 | 72 | 0.160 |
Why?
|
| Canagliflozin | 1 | 2018 | 5 | 0.160 |
Why?
|
| Armed Conflicts | 1 | 2018 | 3 | 0.150 |
Why?
|
| Health Status | 2 | 2016 | 449 | 0.150 |
Why?
|
| Exposure to Violence | 1 | 2018 | 5 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 3 | 2015 | 196 | 0.150 |
Why?
|
| Education | 1 | 2018 | 74 | 0.150 |
Why?
|
| Health Facilities | 1 | 2018 | 43 | 0.150 |
Why?
|
| Comparative Effectiveness Research | 3 | 2013 | 46 | 0.150 |
Why?
|
| Quality Control | 1 | 2018 | 70 | 0.150 |
Why?
|
| Health Education | 1 | 2019 | 184 | 0.150 |
Why?
|
| Multiple Chronic Conditions | 1 | 2018 | 34 | 0.150 |
Why?
|
| Cooperative Behavior | 1 | 2019 | 220 | 0.150 |
Why?
|
| Crime Victims | 1 | 2018 | 32 | 0.150 |
Why?
|
| Osteoporotic Fractures | 1 | 2018 | 32 | 0.150 |
Why?
|
| Budesonide | 2 | 2023 | 10 | 0.150 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2017 | 6 | 0.150 |
Why?
|
| Respiratory Function Tests | 2 | 2009 | 165 | 0.140 |
Why?
|
| Torture | 2 | 2008 | 2 | 0.140 |
Why?
|
| Metformin | 2 | 2015 | 67 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 715 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2018 | 205 | 0.140 |
Why?
|
| Insulin Detemir | 1 | 2016 | 1 | 0.140 |
Why?
|
| Glucagon-Like Peptides | 1 | 2016 | 1 | 0.140 |
Why?
|
| Insulin Glargine | 1 | 2016 | 2 | 0.140 |
Why?
|
| Insulin, Long-Acting | 1 | 2016 | 2 | 0.140 |
Why?
|
| Liraglutide | 1 | 2016 | 4 | 0.140 |
Why?
|
| Observer Variation | 1 | 2017 | 201 | 0.140 |
Why?
|
| Medical Records | 1 | 2017 | 138 | 0.140 |
Why?
|
| Stress, Psychological | 2 | 2014 | 443 | 0.140 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 2470 | 0.140 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 30 | 0.130 |
Why?
|
| Androgens | 1 | 2016 | 48 | 0.130 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2016 | 48 | 0.130 |
Why?
|
| Thiamine Deficiency | 2 | 2007 | 6 | 0.130 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2006 | 94 | 0.130 |
Why?
|
| China | 2 | 2008 | 141 | 0.130 |
Why?
|
| Drug Evaluation | 1 | 2016 | 20 | 0.130 |
Why?
|
| Widowhood | 1 | 2016 | 4 | 0.130 |
Why?
|
| Surge Capacity | 1 | 2015 | 1 | 0.130 |
Why?
|
| Research | 2 | 2015 | 191 | 0.130 |
Why?
|
| Social Isolation | 1 | 2016 | 28 | 0.130 |
Why?
|
| Hypoglycemia | 1 | 2016 | 68 | 0.130 |
Why?
|
| Drug Interactions | 2 | 2007 | 115 | 0.130 |
Why?
|
| Registries | 1 | 2019 | 803 | 0.130 |
Why?
|
| Insurance Claim Review | 1 | 2015 | 80 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 1095 | 0.130 |
Why?
|
| Rosuvastatin Calcium | 2 | 2005 | 3 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2020 | 846 | 0.120 |
Why?
|
| Violence | 2 | 2007 | 149 | 0.120 |
Why?
|
| Checklist | 1 | 2016 | 75 | 0.120 |
Why?
|
| Comorbidity | 1 | 2018 | 1091 | 0.120 |
Why?
|
| Altruism | 1 | 2014 | 13 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 502 | 0.120 |
Why?
|
| Adrenomedullin | 1 | 2014 | 4 | 0.120 |
Why?
|
| Publishing | 1 | 2016 | 90 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 262 | 0.120 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 322 | 0.120 |
Why?
|
| Protein Precursors | 1 | 2014 | 72 | 0.120 |
Why?
|
| Health Services Needs and Demand | 2 | 2007 | 214 | 0.120 |
Why?
|
| Aspirin | 1 | 2015 | 186 | 0.110 |
Why?
|
| Health Services Research | 1 | 2015 | 270 | 0.110 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2013 | 2 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2006 | 372 | 0.110 |
Why?
|
| Bibliometrics | 1 | 2013 | 27 | 0.110 |
Why?
|
| Dutasteride | 1 | 2013 | 1 | 0.110 |
Why?
|
| Pakistan | 1 | 2013 | 14 | 0.110 |
Why?
|
| Prostatic Diseases | 1 | 2013 | 7 | 0.110 |
Why?
|
| Publications | 1 | 2013 | 28 | 0.110 |
Why?
|
| Sitagliptin Phosphate | 1 | 2013 | 2 | 0.110 |
Why?
|
| Time Factors | 3 | 2011 | 3579 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 537 | 0.110 |
Why?
|
| Sex Workers | 1 | 2013 | 17 | 0.110 |
Why?
|
| Meditation | 1 | 2014 | 60 | 0.110 |
Why?
|
| Bone Density | 2 | 2018 | 173 | 0.110 |
Why?
|
| Tetrabenazine | 1 | 2013 | 1 | 0.110 |
Why?
|
| Emergency Medicine | 1 | 2015 | 185 | 0.110 |
Why?
|
| Affect | 1 | 2014 | 121 | 0.110 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2013 | 14 | 0.110 |
Why?
|
| Pyrazines | 1 | 2013 | 32 | 0.110 |
Why?
|
| Social Support | 1 | 2016 | 358 | 0.110 |
Why?
|
| Drug Recalls | 1 | 2012 | 1 | 0.110 |
Why?
|
| Triazoles | 1 | 2013 | 53 | 0.100 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2013 | 75 | 0.100 |
Why?
|
| Therapeutic Equivalency | 1 | 2012 | 9 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 125 | 0.100 |
Why?
|
| Endpoint Determination | 1 | 2012 | 24 | 0.100 |
Why?
|
| Histamine H2 Antagonists | 1 | 2012 | 11 | 0.100 |
Why?
|
| Bayes Theorem | 2 | 2023 | 108 | 0.100 |
Why?
|
| Neoplasms | 2 | 2015 | 1243 | 0.100 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2012 | 34 | 0.100 |
Why?
|
| MP3-Player | 1 | 2011 | 2 | 0.100 |
Why?
|
| Suicidal Ideation | 1 | 2013 | 113 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 1023 | 0.090 |
Why?
|
| Fluticasone | 1 | 2011 | 13 | 0.090 |
Why?
|
| Androstadienes | 1 | 2011 | 30 | 0.090 |
Why?
|
| Huntington Disease | 1 | 2013 | 146 | 0.090 |
Why?
|
| Neuromuscular Diseases | 1 | 2021 | 23 | 0.090 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2013 | 252 | 0.090 |
Why?
|
| Health Care Rationing | 2 | 2015 | 21 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2012 | 553 | 0.090 |
Why?
|
| Mental Disorders | 2 | 2009 | 766 | 0.090 |
Why?
|
| Salmeterol Xinafoate | 1 | 2010 | 4 | 0.090 |
Why?
|
| Albuterol | 1 | 2010 | 20 | 0.090 |
Why?
|
| Observation | 1 | 2010 | 30 | 0.090 |
Why?
|
| Reference Values | 1 | 2011 | 321 | 0.090 |
Why?
|
| Patient Satisfaction | 2 | 2011 | 410 | 0.090 |
Why?
|
| Biomechanical Phenomena | 1 | 2021 | 242 | 0.090 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 13 | 0.090 |
Why?
|
| Symptom Assessment | 1 | 2020 | 39 | 0.090 |
Why?
|
| Needs Assessment | 2 | 2015 | 188 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2012 | 328 | 0.080 |
Why?
|
| Technology, Pharmaceutical | 1 | 2009 | 19 | 0.080 |
Why?
|
| Logistic Models | 1 | 2013 | 1252 | 0.080 |
Why?
|
| Respiratory Aspiration | 1 | 2009 | 6 | 0.080 |
Why?
|
| Program Evaluation | 2 | 2011 | 484 | 0.080 |
Why?
|
| Anti-Retroviral Agents | 1 | 2009 | 73 | 0.080 |
Why?
|
| Sodium Bicarbonate | 1 | 2008 | 11 | 0.080 |
Why?
|
| Bronchoscopy | 1 | 2009 | 64 | 0.080 |
Why?
|
| Latin America | 1 | 2008 | 15 | 0.080 |
Why?
|
| Africa | 1 | 2008 | 21 | 0.080 |
Why?
|
| Japan | 1 | 2008 | 57 | 0.080 |
Why?
|
| Russia | 1 | 2008 | 53 | 0.080 |
Why?
|
| Foreign Bodies | 1 | 2009 | 43 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2009 | 91 | 0.080 |
Why?
|
| Taiwan | 2 | 2021 | 8 | 0.080 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2018 | 12 | 0.080 |
Why?
|
| Scleroderma, Systemic | 1 | 2018 | 14 | 0.080 |
Why?
|
| Thiamine | 2 | 2007 | 19 | 0.080 |
Why?
|
| Tibet | 2 | 2006 | 2 | 0.080 |
Why?
|
| Government Regulation | 1 | 2008 | 44 | 0.080 |
Why?
|
| Research Support as Topic | 1 | 2008 | 44 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2008 | 773 | 0.080 |
Why?
|
| Drug Industry | 1 | 2008 | 40 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 254 | 0.080 |
Why?
|
| Health Personnel | 2 | 2018 | 341 | 0.080 |
Why?
|
| Kidney Function Tests | 1 | 2008 | 34 | 0.080 |
Why?
|
| Sex Factors | 1 | 2021 | 960 | 0.070 |
Why?
|
| India | 1 | 2008 | 157 | 0.070 |
Why?
|
| Nephrology | 1 | 2008 | 15 | 0.070 |
Why?
|
| Anti-HIV Agents | 2 | 2006 | 155 | 0.070 |
Why?
|
| Sulfonylurea Compounds | 2 | 2020 | 14 | 0.070 |
Why?
|
| Recurrence | 2 | 2012 | 578 | 0.070 |
Why?
|
| Causality | 1 | 2008 | 56 | 0.070 |
Why?
|
| Cardiac Output, Low | 1 | 2007 | 10 | 0.070 |
Why?
|
| Rwanda | 1 | 2007 | 12 | 0.070 |
Why?
|
| Postgastrectomy Syndromes | 1 | 2007 | 4 | 0.070 |
Why?
|
| Malabsorption Syndromes | 1 | 2007 | 4 | 0.070 |
Why?
|
| Anecdotes as Topic | 1 | 2007 | 10 | 0.070 |
Why?
|
| Toxins, Biological | 1 | 2007 | 6 | 0.070 |
Why?
|
| Patient Care Planning | 1 | 2008 | 83 | 0.070 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 63 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2009 | 137 | 0.070 |
Why?
|
| New York City | 1 | 2007 | 75 | 0.070 |
Why?
|
| Internet | 1 | 2011 | 458 | 0.070 |
Why?
|
| Homicide | 1 | 2007 | 25 | 0.070 |
Why?
|
| Public Policy | 1 | 2008 | 41 | 0.070 |
Why?
|
| Homosexuality, Male | 1 | 2007 | 38 | 0.070 |
Why?
|
| Health Policy | 2 | 2008 | 185 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2020 | 1839 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 2592 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2008 | 159 | 0.070 |
Why?
|
| Communicable Disease Control | 1 | 2007 | 38 | 0.070 |
Why?
|
| Anxiety | 2 | 2014 | 395 | 0.070 |
Why?
|
| Catheterization, Central Venous | 1 | 2008 | 87 | 0.070 |
Why?
|
| Theft | 1 | 2006 | 3 | 0.070 |
Why?
|
| Developed Countries | 1 | 2006 | 15 | 0.070 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 158 | 0.070 |
Why?
|
| Educational Status | 1 | 2008 | 271 | 0.070 |
Why?
|
| Safety | 1 | 2007 | 141 | 0.070 |
Why?
|
| Communicable Diseases | 1 | 2007 | 82 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2007 | 161 | 0.070 |
Why?
|
| Minority Groups | 1 | 2008 | 140 | 0.070 |
Why?
|
| Vascular Neoplasms | 1 | 2006 | 15 | 0.070 |
Why?
|
| Infant Mortality | 1 | 2006 | 19 | 0.070 |
Why?
|
| HIV | 1 | 2006 | 69 | 0.070 |
Why?
|
| Police | 1 | 2006 | 37 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2007 | 225 | 0.070 |
Why?
|
| Expert Systems | 1 | 2006 | 6 | 0.070 |
Why?
|
| Life Change Events | 1 | 2006 | 66 | 0.070 |
Why?
|
| Biomarkers | 2 | 2014 | 1210 | 0.070 |
Why?
|
| Penicillins | 1 | 2006 | 28 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2008 | 296 | 0.070 |
Why?
|
| Ethics, Research | 1 | 2006 | 19 | 0.060 |
Why?
|
| Likelihood Functions | 1 | 2006 | 73 | 0.060 |
Why?
|
| Vasoconstriction | 1 | 2006 | 19 | 0.060 |
Why?
|
| Pregnancy | 1 | 2013 | 2355 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2006 | 65 | 0.060 |
Why?
|
| Endarterectomy, Carotid | 1 | 2006 | 87 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 694 | 0.060 |
Why?
|
| AIDS Vaccines | 1 | 2006 | 67 | 0.060 |
Why?
|
| Maternal Health Services | 1 | 2006 | 64 | 0.060 |
Why?
|
| Child Health Services | 1 | 2006 | 64 | 0.060 |
Why?
|
| Thrombosis | 1 | 2008 | 195 | 0.060 |
Why?
|
| Condoms | 1 | 2005 | 47 | 0.060 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2006 | 71 | 0.060 |
Why?
|
| Diabetic Nephropathies | 1 | 2005 | 38 | 0.060 |
Why?
|
| Horner Syndrome | 1 | 2005 | 1 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2008 | 327 | 0.060 |
Why?
|
| Communism | 1 | 2004 | 1 | 0.060 |
Why?
|
| War Crimes | 1 | 2004 | 2 | 0.060 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2005 | 13 | 0.060 |
Why?
|
| Nutrition Disorders | 1 | 2004 | 5 | 0.060 |
Why?
|
| Educational Measurement | 1 | 2006 | 207 | 0.060 |
Why?
|
| Principle-Based Ethics | 1 | 2004 | 2 | 0.060 |
Why?
|
| Poverty | 1 | 2007 | 286 | 0.060 |
Why?
|
| Cyclopropanes | 2 | 2016 | 41 | 0.060 |
Why?
|
| Psychology, Child | 1 | 2004 | 7 | 0.060 |
Why?
|
| Resource Allocation | 1 | 2004 | 20 | 0.060 |
Why?
|
| Infant | 2 | 2006 | 1527 | 0.060 |
Why?
|
| Rural Health | 1 | 2004 | 15 | 0.060 |
Why?
|
| Family Practice | 1 | 2006 | 204 | 0.060 |
Why?
|
| Health Planning | 1 | 2004 | 30 | 0.060 |
Why?
|
| Malaria, Vivax | 1 | 2005 | 33 | 0.060 |
Why?
|
| Education, Medical | 1 | 2006 | 175 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2004 | 57 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2006 | 223 | 0.060 |
Why?
|
| Total Quality Management | 1 | 2004 | 58 | 0.060 |
Why?
|
| Child Advocacy | 1 | 2004 | 7 | 0.060 |
Why?
|
| Massachusetts | 2 | 2021 | 2089 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 307 | 0.060 |
Why?
|
| Morbidity | 1 | 2004 | 109 | 0.060 |
Why?
|
| Tachycardia, Ventricular | 1 | 2006 | 118 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2004 | 112 | 0.060 |
Why?
|
| Gastric Bypass | 1 | 2004 | 74 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2024 | 250 | 0.060 |
Why?
|
| Medicaid | 2 | 2019 | 335 | 0.060 |
Why?
|
| Africa South of the Sahara | 3 | 2009 | 17 | 0.060 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2023 | 4 | 0.050 |
Why?
|
| Pyridones | 1 | 2023 | 35 | 0.050 |
Why?
|
| Trust | 1 | 2024 | 68 | 0.050 |
Why?
|
| Factor Xa Inhibitors | 1 | 2023 | 36 | 0.050 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 72 | 0.050 |
Why?
|
| Fluvoxamine | 1 | 2023 | 1 | 0.050 |
Why?
|
| Students, Medical | 1 | 2006 | 243 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 900 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2023 | 70 | 0.050 |
Why?
|
| Mobile Applications | 1 | 2024 | 130 | 0.050 |
Why?
|
| Embolization, Therapeutic | 1 | 2006 | 307 | 0.050 |
Why?
|
| Stents | 1 | 2006 | 443 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 303 | 0.050 |
Why?
|
| United States Agency for Healthcare Research and Quality | 2 | 2012 | 30 | 0.050 |
Why?
|
| Curriculum | 1 | 2006 | 550 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2023 | 113 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 645 | 0.050 |
Why?
|
| Intention | 1 | 2022 | 66 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2006 | 1311 | 0.050 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2021 | 45 | 0.050 |
Why?
|
| Glucosides | 1 | 2020 | 13 | 0.040 |
Why?
|
| Liver | 1 | 2005 | 785 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 559 | 0.040 |
Why?
|
| Interviews as Topic | 2 | 2016 | 486 | 0.040 |
Why?
|
| Tennessee | 1 | 2019 | 16 | 0.040 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2019 | 13 | 0.040 |
Why?
|
| Benzhydryl Compounds | 1 | 2020 | 48 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2004 | 679 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1225 | 0.040 |
Why?
|
| Clinical Coding | 1 | 2019 | 43 | 0.040 |
Why?
|
| United Nations | 2 | 2009 | 4 | 0.040 |
Why?
|
| Government | 1 | 2018 | 7 | 0.040 |
Why?
|
| Bombs | 1 | 2018 | 3 | 0.040 |
Why?
|
| Syria | 1 | 2018 | 12 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2018 | 25 | 0.040 |
Why?
|
| Propensity Score | 1 | 2018 | 134 | 0.040 |
Why?
|
| Mass Casualty Incidents | 1 | 2018 | 31 | 0.040 |
Why?
|
| Health Resources | 1 | 2018 | 88 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1032 | 0.030 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2015 | 9 | 0.030 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2015 | 14 | 0.030 |
Why?
|
| Quetiapine Fumarate | 1 | 2015 | 13 | 0.030 |
Why?
|
| Selection Bias | 1 | 2015 | 24 | 0.030 |
Why?
|
| Neuralgia | 1 | 2015 | 20 | 0.030 |
Why?
|
| Amines | 1 | 2015 | 30 | 0.030 |
Why?
|
| Heparin | 2 | 2008 | 113 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1044 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2015 | 79 | 0.030 |
Why?
|
| Analgesics | 1 | 2015 | 100 | 0.030 |
Why?
|
| Triage | 1 | 2015 | 110 | 0.030 |
Why?
|
| Community-Acquired Infections | 1 | 2014 | 87 | 0.030 |
Why?
|
| Placebos | 1 | 2013 | 72 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2016 | 264 | 0.030 |
Why?
|
| Enoxaparin | 1 | 2013 | 15 | 0.030 |
Why?
|
| Emotions | 1 | 2016 | 217 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 673 | 0.030 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2013 | 27 | 0.030 |
Why?
|
| Nasal Sprays | 1 | 2012 | 2 | 0.030 |
Why?
|
| Bipolar Disorder | 1 | 2015 | 254 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2012 | 31 | 0.030 |
Why?
|
| Computer Graphics | 1 | 2012 | 23 | 0.030 |
Why?
|
| International Normalized Ratio | 1 | 2011 | 34 | 0.020 |
Why?
|
| Critical Care | 1 | 2015 | 411 | 0.020 |
Why?
|
| North Carolina | 1 | 2011 | 66 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2012 | 137 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2013 | 170 | 0.020 |
Why?
|
| Computer-Assisted Instruction | 1 | 2011 | 81 | 0.020 |
Why?
|
| Patient Preference | 1 | 2011 | 76 | 0.020 |
Why?
|
| Health Literacy | 1 | 2011 | 77 | 0.020 |
Why?
|
| Voluntary Health Agencies | 1 | 2009 | 4 | 0.020 |
Why?
|
| Rape | 1 | 2009 | 14 | 0.020 |
Why?
|
| Body Weight | 1 | 2011 | 378 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2008 | 57 | 0.020 |
Why?
|
| Lipids | 1 | 2011 | 306 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 261 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 170 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2009 | 183 | 0.020 |
Why?
|
| Bhutan | 1 | 2008 | 20 | 0.020 |
Why?
|
| Myanmar | 1 | 2007 | 8 | 0.020 |
Why?
|
| Elephantiasis, Filarial | 1 | 2007 | 9 | 0.020 |
Why?
|
| Yellow Fever | 1 | 2007 | 3 | 0.020 |
Why?
|
| Animals | 1 | 2006 | 19661 | 0.020 |
Why?
|
| Colombia | 1 | 2007 | 14 | 0.020 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2007 | 12 | 0.020 |
Why?
|
| Half-Life | 1 | 2007 | 70 | 0.020 |
Why?
|
| Chagas Disease | 1 | 2007 | 34 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 53 | 0.020 |
Why?
|
| Hunger | 1 | 2006 | 17 | 0.020 |
Why?
|
| Time | 1 | 2006 | 27 | 0.020 |
Why?
|
| Social Welfare | 1 | 2006 | 22 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2006 | 55 | 0.020 |
Why?
|
| North America | 1 | 2006 | 114 | 0.020 |
Why?
|
| Coercion | 1 | 2006 | 53 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2006 | 113 | 0.020 |
Why?
|
| Lymphoma, B-Cell | 1 | 2006 | 59 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 2006 | 43 | 0.020 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2006 | 4 | 0.020 |
Why?
|
| Cambodia | 1 | 2005 | 18 | 0.020 |
Why?
|
| Confidentiality | 1 | 2006 | 52 | 0.020 |
Why?
|
| Self-Help Groups | 1 | 2005 | 37 | 0.020 |
Why?
|
| Attitude | 1 | 2006 | 100 | 0.020 |
Why?
|
| Prisons | 1 | 2006 | 114 | 0.020 |
Why?
|
| Quinine | 1 | 2005 | 3 | 0.020 |
Why?
|
| Chloroquine | 1 | 2005 | 48 | 0.020 |
Why?
|
| Doxycycline | 1 | 2005 | 41 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 2005 | 44 | 0.020 |
Why?
|
| Informed Consent | 1 | 2006 | 133 | 0.020 |
Why?
|
| Antimalarials | 1 | 2005 | 68 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2005 | 155 | 0.010 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2008 | 367 | 0.010 |
Why?
|